Deutsche Bank AG reduced its holdings in shares of Forty Seven Inc (NASDAQ:FTSV) by 53.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,673 shares of the company’s stock after selling 8,683 shares during the period. Deutsche Bank AG’s holdings in Forty Seven were worth $119,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the business. BlackRock Inc. increased its stake in shares of Forty Seven by 1,203.9% in the third quarter. BlackRock Inc. now owns 446,363 shares of the company’s stock worth $6,659,000 after purchasing an additional 412,129 shares in the last quarter. Exane Asset Management purchased a new stake in shares of Forty Seven in the fourth quarter worth $424,000. Bank of New York Mellon Corp purchased a new stake in shares of Forty Seven in the third quarter worth $196,000. JPMorgan Chase & Co. increased its stake in shares of Forty Seven by 51.2% in the third quarter. JPMorgan Chase & Co. now owns 346,066 shares of the company’s stock worth $5,164,000 after purchasing an additional 117,142 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of Forty Seven by 144.4% in the third quarter. Vanguard Group Inc. now owns 171,060 shares of the company’s stock worth $2,553,000 after purchasing an additional 101,060 shares in the last quarter. 47.34% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ:FTSV opened at $11.30 on Tuesday. Forty Seven Inc has a fifty-two week low of $10.50 and a fifty-two week high of $23.83. The firm has a market cap of $354.67 million and a P/E ratio of -3.01.

Forty Seven (NASDAQ:FTSV) last issued its earnings results on Monday, May 13th. The company reported ($0.74) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.14). On average, analysts expect that Forty Seven Inc will post -2.72 EPS for the current year.

In related news, insider Mark Anthony Mccamish sold 16,500 shares of the company’s stock in a transaction on Monday, May 20th. The shares were sold at an average price of $12.10, for a total transaction of $199,650.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Ravindra Majeti sold 35,000 shares of the company’s stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $17.83, for a total transaction of $624,050.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 169,811 shares of company stock valued at $2,921,746. 37.40% of the stock is owned by company insiders.

A number of analysts have recently issued reports on the stock. Roth Capital assumed coverage on shares of Forty Seven in a research note on Wednesday, May 29th. They issued a “buy” rating and a $28.00 price objective for the company. Zacks Investment Research raised shares of Forty Seven from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a research note on Tuesday, May 14th. HC Wainwright set a $21.00 price objective on shares of Forty Seven and gave the stock a “buy” rating in a research note on Tuesday, May 14th. Guggenheim assumed coverage on shares of Forty Seven in a research note on Friday, April 12th. They issued a “buy” rating for the company. Finally, Oppenheimer reissued a “buy” rating on shares of Forty Seven in a research note on Tuesday, March 19th. One analyst has rated the stock with a hold rating and ten have given a buy rating to the company. Forty Seven presently has an average rating of “Buy” and a consensus target price of $26.89.

ILLEGAL ACTIVITY WARNING: This piece was first published by Daily Political and is the property of of Daily Political. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The correct version of this piece can be accessed at https://www.dailypolitical.com/2019/06/04/deutsche-bank-ag-trims-holdings-in-forty-seven-inc-ftsv.html.

About Forty Seven

Forty Seven Inc, a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody.

Featured Story: P/E Growth (PEG)

Want to see what other hedge funds are holding FTSV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Forty Seven Inc (NASDAQ:FTSV).

Institutional Ownership by Quarter for Forty Seven (NASDAQ:FTSV)

Receive News & Ratings for Forty Seven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forty Seven and related companies with MarketBeat.com's FREE daily email newsletter.